Eloxx Pharmaceuticals Inc ELOX:NASDAQ

RT Quote | NASDAQ | USD
Last | 03/05/21 EST
3.61quote price arrow down-0.16 (-4.24%)
Volume
103,686
52 week range
1.44 - 6.77

...

Loading . . .

KEY STATS

  • Open3.77
  • Day High3.82
  • Day Low3.25
  • Prev Close3.77
  • 52 Week High6.77
  • 52 Week High Date12/17/20
  • 52 Week Low1.44
  • 52 Week Low Date04/03/20
  • Market Cap144.94M
  • Shares Out40.15M
  • 10 Day Average Volume0.16M
  • Dividend-
  • Dividend Yield-
  • Beta2.75
  • 1 Year % Change4.64

RATIOS/PROFITABILITY

  • EPS (TTM)-1.00
  • P/E (TTM)-3.61
  • Fwd P/E (NTM)-4.54
  • EBITDA (MRQ)-35.072M
  • ROE (MRQ)-132.93%
  • Revenue (MRQ)0.00
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)84.49%

EVENTS

  • Earnings Date03/10/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Eloxx Pharmaceuticals Inc News

There is no recent news for this security.

Latest ELOX News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing ribonucleic acid (RNA)-modulating drug candidates, which are designed to be eukaryotic ribosomal selective glycosides (ERSG). It is developing its drug candidates for treating rare and ultra-rare premature stop codon diseases. ELX-02 is its lead investigational drug product candidate. ELX-02 is a small molecule drug candidate designed to restore production of...
Tomer Kariv J.D.
Chairman
Gregory Williams Ph.D.
Chief Executive Officer
Neil Belloff
Chief Operating Officer
Stephen MacDonald
Chief Accounting Officer
Address
950 Winter St
Waltham, MA
02451-1424
United States